Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Cyclacel Pharma (CYCC) Reports Q4 Loss of $0.62
March 27, 2019 4:10 PM EDTCyclacel Pharma (NASDAQ: CYCC) reported Q4 EPS of ($0.62), versus ($1.95) reported last year. Revenue for the quarter came in at $150 thousand, versus $0 reported last year.
"We are executing on our targeted oncology strategy with the objective of delivering data readouts from multiple clinical programs, said Spiro Rombotis, President... More
